Descripción del proyecto
Biomarcadores de hipertensión a partir de microARN
La hipertensión es la principal causa de enfermedad cardiovascular y afecta a cerca de un tercio de la población mundial. Dado que su diagnóstico y su tratamiento se han mantenido sin cambios durante años, los científicos participantes en el proyecto financiado con fondos europeos MITO están investigando nuevos métodos para mejorar la atención sanitaria de los pacientes hipertensos. Los trabajos se centrarán en el descubrimiento de microARN mitocondrial en la sangre de pacientes hipertensos. Estas pequeñas moléculas reguladoras constituyen una fuente accesible de biomarcadores y se han utilizado ampliamente como dianas terapéuticas en aplicaciones clínicas. Los investigadores también están interesados en estudiar el papel del microARN en el desarrollo de la hipertensión, con el objetivo de preparar el camino para el descubrimiento de nuevos agentes antihipertensivos.
Objetivo
Hypertension is an extreme public health problem affecting nearly one third of the World’s adult population. Most cardiovascular diseases are provoked by hypertension resulting in an estimated 9.4 million deaths every year. Surprisingly, the diagnosis of hypertension has changed very little over the past 100 years - just using a stethoscope definitely needs refining. Furthermore, the epidemic proportion of hypertension worldwide pinpoints the necessity for the discovery of fresh antihypertensive therapies. Thus the main objective of the MITO project is to discover novel methods to improve healthcare of hypertension patients. For this we will investigate the circulating pool of microRNAs (small RNA molecules present in the blood, regulating gene expression) - we hypothesize that particularly mitochondrial microRNAs play a critical role in hypertension development. Easily obtainable in the blood, microRNAs constitute an accessible source of biomarkers and therapeutic targets for clinical application. The research plan envisages three scientific work packages dedicated (1) to the discovery of candidate microRNAs associated with hypertension by using small RNA sequencing in 30 hypertensive patients and 30 controls, (2) the validation of candidate microRNAs in a group of 540 participants (paying attention to sex specificities), and (3) to the functional assessment of the role of microRNAs in hypertension development. While the first two parts of the project will be conducted at the host institution in Luxembourg, functional studies will involve three secondments to partner institutions in Denmark, Germany, and France. A successful outcome will have implications ranging from contributing to satisfy the need for novel methods to stop the progression of hypertension, to a better understanding of the role of microRNAs in hypertension development, to the training of a young East European researcher to pioneer development in a research field just emerging in her home country.
Ámbito científico
Programa(s)
Régimen de financiación
MSCA-IF - Marie Skłodowska-Curie Individual Fellowships (IF)Coordinador
1445 Strassen
Luxemburgo